Peter Nash drpnash
5 years 11 months ago
Association of Hydroxychloroquine Use with Development of Non-Alcoholic Fatty Liver Disease in Rheumatoid Arthritis https://t.co/3PrWlIGnB8 #RA #HCO #NASH - HCO decreases fatty liver
Peter Nash drpnash
5 years 11 months ago
Lymphomas Complicating Rheumatoid Arthritis: Results of a French Multi-Centre Case-Control Study https://t.co/NDk0LH5Kk6 #RA #lymphoma risk driven by increased disease activity
Peter Nash drpnash
5 years 11 months ago
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis https://t.co/i456zSn6Ba #RA #Baricitinib #safety 13000 pt/yrs 8.4 yrs F/U no new safety signals VTE 0.5/100 pt yrs
Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020. This is our selection of their best studies for you to review and evaluate as part of your to-do list.
alexa meara lexmeara
5 years 11 months ago
COVID-19 use of dexamethasone- why does it work? When to use it ?Is it hyperferrintemic sepsis? Vs early MAS vs? More data needed but this why rheumatologists are needed!!! @RheumNow #ACR20 thank you dr. Rubin! https://t.co/MvQJGqsqu2
k dao KDAO2011
5 years 11 months ago
What is your top concern about the SARS-Co-V2 vaccine for rheum patients? @RheumNow #ACR20
Rheum Cat rheum_cat
5 years 11 months ago
@JYazdanyMD @UWRheum @r_burmester Black, et al - cont'd
277 atypical femur fx events
Risk increased w longer duration of bisphosphonate use
Risk decreased after bisphosphonate discontinuation
Asians had a higher risk than Whites.
#ACR20 #ACRambassador
Dr Irwin Lim _connectedcare
5 years 11 months ago
New drug mechanisms for SpA. Nice to have expanding options
#ACR20 https://t.co/vlTwaiuuS3
k dao KDAO2011
5 years 11 months ago
4.CIRT: low dose MTX 15 mg/week: transaminitis NNH 6,
cirrhosis NNH 1000
5.LoDoCo2: colchicine prevents MACE: NNT 36
6.ENTRACTE: TCZ vs ETN: for bowel perforation TCZ:
NNH 600
Mrinalini Dey DrMiniDey
5 years 11 months ago
Year in Review by @JYazdanyMD: #Cardiovascular #Inflammation Reduction Trial provided "unique opportunity to learn about side-effects" of a drug we commonly use.
Low-dose MTX assoc. with small-mod. elevated risk of transaminitis, infection, anaemia & skin cancer.
#ACR20 @RheumNow https://t.co/hNS600Pndr
Eric Dein ejdein1
5 years 11 months ago
How do you monitor HCQ on patients with chronic QTc prolonging medications (ex psychiatric meds)? @JYazdanyMD Year-in-Review #ACR20 @rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD
5 years 11 months ago
Do you plan to do a skin exam in your RA patients on MTX given new toxicity signal of skin cancer based on CIRT with NNH of 167? @JYazdanyMD #ACR20 Year in Review @RheumNow
Jeff Sparks jeffsparks
5 years 11 months ago
Dr Kevin Wei's study with @ilyakorsunsky @Deepakarao @soumya_boston, Dr. Michael Brenner and others at @BrighamResearch featured in the basic year-in-review at #ACR20 showing Notch signaling importance in synovium from arthritis #ACRambassador
Richard Conway RichardPAConway
5 years 11 months ago
What is most important clinical study in last year? #ACR20 @rheumnow
Peter Nash drpnash
5 years 11 months ago
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis https://t.co/1kqWeBcEDq #gca #GmCSFinh Novel MOA , big unmet need
